{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:37:42Z","timestamp":1791074262635,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1378\/chest.13-1864","type":"journal-article","created":{"date-parts":[[2013,12,26]],"date-time":"2013-12-26T14:30:55Z","timestamp":1388068255000},"page":"1055-1063","source":"Crossref","is-referenced-by-count":42,"title":["Comparative Effectiveness and Safety of Drug Therapy for Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"145","author":[{"given":"Remy R.","family":"Coeytaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine M.","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej S.","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicea M.","family":"Mingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Vann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Gilstrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. William","family":"Hargett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Heidenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena J.","family":"Dolor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"McCrory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1378\/chest.13-1864_bib1","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1378\/chest.13-1864_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ahj.2009.11.028","article-title":"Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed","volume":"159","author":"Macchia","year":"2010","journal-title":"Am Heart J"},{"key":"10.1378\/chest.13-1864_bib3","unstructured":"D McCrory, R Coeytaux, K Schmit, et al Pulmonary Arterial Hypertension: Screening, Management, and Treatment. Comparative Effectiveness Review No. 117 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) Rockville, MD: Agency for Healthcare Research and Quality; April 2013. AHRQ Publication No. 13-EHC087-EF"},{"issue":"4","key":"10.1378\/chest.13-1864_bib5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1378\/chest.13-1864_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"issue":"9288","key":"10.1378\/chest.13-1864_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1378\/chest.13-1864_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1378\/chest.13-1864_bib9","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1378\/chest.13-1864_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"issue":"9630","key":"10.1378\/chest.13-1864_bib11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1378\/chest.13-1864_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1378\/chest.13-1864_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"issue":"20","key":"10.1378\/chest.13-1864_bib14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1378\/chest.13-1864_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1378\/chest.13-1864_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1378\/chest.13-1864_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1378\/chest.13-1864_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","article-title":"Long-term therapy with inhaled iloprost in patients with pulmonary hypertension","volume":"104","author":"Olschewski","year":"2010","journal-title":"Respir Med"},{"issue":"11","key":"10.1378\/chest.13-1864_bib19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1378\/chest.13-1864_bib20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.13-1864_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1378\/chest.13-1864_bib22","first-page":"323","article-title":"Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension","volume":"59","author":"Bharani","year":"2007","journal-title":"Indian Heart J"},{"issue":"5","key":"10.1378\/chest.13-1864_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1747-0803.2011.00561.x","article-title":"Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome\u2014a randomized, placebo-controlled, double-blind crossover study","volume":"6","author":"Mukhopadhyay","year":"2011","journal-title":"Congenit Heart Dis"},{"issue":"22","key":"10.1378\/chest.13-1864_bib24","first-page":"2894","article-title":"Tadalafil therapy for pulmonary arterial hypertension [published correction appears in .Circulation. 2011; 124(10):e279]","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"issue":"23","key":"10.1378\/chest.13-1864_bib25","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1378\/chest.13-1864_bib26","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1378\/chest.13-1864_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1378\/chest.13-1864_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"18","key":"10.1378\/chest.13-1864_bib29","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1378\/chest.13-1864_bib30","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1378\/chest.13-1864_bib31","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.amjcard.2011.06.021","article-title":"Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension","volume":"108","author":"Fox","year":"2011","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1378\/chest.13-1864_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1378\/chest.13-1864_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1378\/chest.13-1864_bib34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Gali\u00e8","year":"2009","journal-title":"Eur Respir J"},{"issue":"20","key":"10.1378\/chest.13-1864_bib35","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215345980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215345980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:39:57Z","timestamp":1655944797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215345980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0012369215345980"],"URL":"https:\/\/doi.org\/10.1378\/chest.13-1864","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}